Lakefront Biotherapeutics NV — Company profile
Belgium
Last price 32.23 USD (Oct 30, 2026, 1:55 PM EDT) · Market cap 2.06B
Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports
Company profile
Lakefront Biotherapeutics NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company’s pipeline products comprise GLPG3667, which is in a phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in a phase 1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was formerly known as Galapagos NV and changed its name to Lakefront Biotherapeutics NV in May 2026. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.
Details
| Name | Lakefront Biotherapeutics NV |
| Sector | Healthcare |
| Industry | Biotechnology |
| Employees | 196 |
| Founded | 1999 |
| Ceo | Henry Gosebruch |
| Country | Belgium |
| Exchange | NASDAQ |
| Fiscal Year | January - December |
| Reporting Currency | EUR |
| Isin | US36315X1019 |
| Cusip | 36315X101 |
| Cik | 1421876 |
| Sic | 2834 |
Key executives
| Name | Title |
|---|---|
| Henry O. Gosebruch | Chief Executive Officer and Executive Director |
| Aaron L. Cox | Chief Financial Officer |
| Christina Carlson J.D. | Chief Operating Officer |
| Dr. Glenn Schulman M.P.H., Pharm. D., Pharm.D. | Head of Investor Relations |
| Fred W. Blakeslee II | Executive Vice President and General Counsel |
| Marieke Vermeersch | Head of Corporate Communication |
| Tania Philipp | Chief People Officer |
| Ellen Van Der Aar | Head of Development |
| Dr. Jeevan Shetty | Head of Clinical Development Oncology |
| Ruiz Astigarraga | Head of Manufacturing Cell Therapy |
Contact
| Address | SchaliEnhoevedreef 20 T, Mechelen, 2800, Belgium |
| Phone | 32 1 534 29 00 |
| Website | https://lakefrontbio.com |